This is minor insight ... Friday May 1 2009
At http://www.guardian.co.uk/business/feedarticle/8484264
Treating just 1 percent of the population in a local epidemic with Relenza rather than Tamiflu could substantially delay the emergence of resistance to Tamiflu, scientists said.
Tamiflu, which is taken as a tablet, is more convenient than Relenza, or zanamivir, which must be inhaled. Tamiflu and Relenza are the only approved drugs to which the new H1N1 strain has been found to be susceptible.
Roche and Glaxo are both expected to enjoy windfall gains from sales of their medicines, and the two companies are racing to increase production capacity to keep up with demand.
I would consider that a 1 percent of the population treatment would benefit BTA by 70 800 000,
where pop = 6740000000
per packet = $15 (hard to define on a world-wide basis)
and 7% royalty.
I have further modelling but would like better stockpiling forecasts.
Either way, BTA management seem to be holding back re best interests of shareholders and long term gains are a competitive and likely.
- Forums
- ASX - By Stock
- BTA
- why is tamiflu always mentioned
why is tamiflu always mentioned, page-3
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online